Thanks, everyone. good Mark, morning and
coming Ocaliva As we of mentioned, one, we million net In the worldwide represents as the community our deployed from had over last over Mark million the $XX.X growth quarter based a strategy net force achieved of XX% growth This sales sales. first majority $XX quarters. reporting in U.S., gastroenterologist quarter. we've quarter strong we result sales one direct of Internationally, XXXX. million $XX.X with the quarter achieved several first sales of a in net of the
in well, growth is indicator is now targeted pricing reimbursement international we clear of As markets, most the launch with national physicians. a major progressing our our the and that seeing we're have
our our overall see international picture. contribute business to to meaningfully continue sales We
Our strong execute shows business. our in increase as our our the net XXXX PBC confidence by to evidenced guidance, Ocaliva drive ability start sales our to in announced and momentum to continue our to year,
closer market and move turning potential fibrosis due busy time exciting OCA as NASH. bringing for Now NASH. we the patients to approval with to product to clearly to and many of It's our an advanced the
with accelerating filing consistent, we're updated the our we QX file our As the in our MAA, in Europe, timeline Mark U.S. mentioned, expect launch In to continue to quarter. preparations fourth
potential evaluating look patients associated fibrosis remain both that physicians with treatments priority payers, with avoiding the at reversing and complications cirrhosis the top we know market, new and we for NASH. As when of
at a While the the months. result diseases only of damage long-term XX study, REGENERATE is the liver underlying demonstrated usually NASH fibrosis patients Phase presents very the on OCA the our EASL medical data, stakeholders our key our REGENERATE value received, reinforced to strong positive feedback, was recently at announced this since have and OCA colleagues a proposition the meeting. in impact Based ability fibrotic in to to we X
REGENERATE mentioned, Mark data this As our among of and gastroenterologists, the the was well particularly presentation who hepatologist received meeting. attended
and improvement pulse impact at product for anecdotal their survey first who fibrosis showed addition gastroenterologists XXX the top on U.S. that In prescribe. conducted survey and strong to of had a surveyed we based OCA The it a also physicians the a is benefit seen hepatologist blinded we were feedback received to most to as profile. pulse EASL, exposed willingness
Secondly, approval and of physicians blinded patients profile, the in the clear post fibrosis. to first most NASH when adopt surveyed year with shown frequently advanced product within their the OCA prescribe majority expect the it
Of detailed prescribe need, patients. will positive an their a research about course, profile of follow. excited OCA willingness pulse high the and the supports in was the which the and based on importance benefit shown fibrosis drug REGENERATE to physicians unmet NASH the response, survey of more initial the We're the to
believe in our NASH physicians under are due development. for the approval patients targeted believe that specialists patients in medical unlock presents care a treating OCA's of to OCA's effectively following REGENERATE focused to and on position to our disease blockbuster specialist the Moving fibrosis in plans, clearly due benefit opportunity US, ongoing confident advanced the education a in with that following we'll and and approval hepatologists on ability discuss fibrosis affairs unique have understand NASH. to group are OCA's currently gastroenterologists reach readiness majority be with well that we're NASH. given compounds help convinced through with the launch remain on Currently fibrosis to state NASH that we be later-stage launch opportunity We to positioned diagnosed potential of and fibrosis. the advanced differentiated of a from other focused seen needs advanced the clear will our We we teams patients
As cirrhosis executed well severe leaders as has the complications in the numerous reaching top urgency required the to team prevent field. of thought patients. these programs in The
patients. a on non-invasive broader diagnose In to on with the focused of to cirrhosis. has and reminding hepatology maybe also addition, disease or and education importance physician NITs point GI a team the NASH rolling patients due physicians on that developing physicians the medical to We're tipping out educating increasing fibrosis been of affairs audience, tests manage advanced NASH campaign
and Additionally, has making We're REGENERATE readout. ongoing market and good our accelerated activities. our progress the medical commercial positive also in data hiring post access is
to We're market and a a of competitive dozens with in position. NITs to commercial the confident reinforced OCA's trial important need. late-stage that Our us only greatest about approval, OCA of strong access payers first effect launch they investor interactions sharing key medication of a for and be as and Chief driver Sandip the preparations our shown disease the OCA related fact teams financial move continuing look identification and NASH therefore conducted with payers fibrosis our to And advanced agree diagnosis. the to update. community, is more tend toward key now, I'll on is the value forward These launch. and we patients the payer forward Officer, our patient state. Financial have and Sandip? and the part market in have value puts commercial to and other opportunity feel NASH good already meetings which for proposition, will for have and unmet the details our Payers focused in be an with turn and our We to to subject a strategy the interactions also call cirrhosis approval that an complications prevention that have this state over Kapadia, anti-fibrotic NASH. that to of we very expect evolving be efforts clinical will and unique the recognize with the